We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3,866.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/1/2024 | 08:15 | UKREG | Dechra Pharmaceuticals PLC Cancellation of listing and admission to trading |
| 17/1/2024 | 08:00 | UKREG | London Stock Exchange Notice Cancellation - Dechra Pharmaceuticals Plc |
| 17/1/2024 | 07:30 | UKREG | Dechra Pharmaceuticals PLC Holding(s) in Company |
| 16/1/2024 | 16:54 | UKREG | Dechra Pharmaceuticals PLC Holding(s) in Company |
| 16/1/2024 | 15:29 | UKREG | Credit Industriel et Commercial Form 8.3 - Dechra Pharmaceuticals plc |
| 16/1/2024 | 15:25 | UKREG | MILLENNIUM PARTNERS: Form 8.3 - Dechra Pharmaceuticals plc |
| 16/1/2024 | 14:43 | UKREG | Dechra Pharmaceuticals PLC Holding(s) in Company |
| 16/1/2024 | 13:31 | UKREG | NATIXIS: Form 8.3 - Dechra Pharmaceuticals plc |
| 16/1/2024 | 13:25 | UKREG | State Street Global Advisors Form 8.3 - Dechra Pharmaceuticals plc |
| 16/1/2024 | 13:15 | UKREG | Barclays PLC Form 8.3 - Dechra Pharmaceuticals plc |
Dechra Pharmaceuticals (DPH) Share Charts1 Year Dechra Pharmaceuticals Chart |
|
1 Month Dechra Pharmaceuticals Chart |
Intraday Dechra Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/9/2023 | 07:39 | Dechra Pharmaceuticals Plc | 629 |
| 10/3/2012 | 16:11 | LOOKING TO BUY DECHRA PHARMACEUTICAL | 88 |
| 10/3/2012 | 16:10 | Dechra with Charts | 9 |
| 10/3/2012 | 16:10 | Dechra Pharmaceuticals PLC | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 05/6/2023 19:27 by robertball I guess the price will hover until we get a CMA announcement.Any idea as to when? |
Posted at 02/6/2023 21:26 by robertball The return is high because the competition authorities might look into the EQT/ Dechra deal.EQT own IVC Evidensia. This is the Luxembourg company which owns Independent Vetcare Limited.They in turn, have a sizeable share of the UK vet and vet hospital market.Also see tomorrow's Lex in the FT |
Posted at 02/6/2023 13:56 by vworlds_cambridge The price is not good for me, but we are where we are. Had bought this for the long-term. Thanks for all the useful info on here. |
Posted at 02/6/2023 06:25 by 1jat Unlikely another bidder will emerge to raise the price so we will never know what the share price would have been……bu |
Posted at 01/6/2023 08:58 by steeplejack Yes i tend to agree.It reads as if tomorrow might well be the 'put up or shut up' deadline.The Company remains in discussion with EQT X EUR SCSp and EQT X USD SCSp, each represented by its manager (gérant) EQT Fund Management S.à r.l. (collectively referred to as "EQT") regarding a possible all-cash recommended offer of 4,070 pence per ordinary share. As announced on 11 May 2023, in accordance with Rule 2.6(a) of the City Code on Takeovers and Mergers (the "Code"), EQT is required, by not later than 5.00 pm (London time) on 2 June 2023 either to announce a firm intention to make an offer for Dechra in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer. |
Posted at 30/5/2023 08:44 by lindowcross Steeple, I agree with your comments at 602 and I'm betting the takeover will proceed at the current mentioned price or close to it. So I bought a few more last week. |
Posted at 22/5/2023 15:32 by steeplejack Yes,the management won’t be that keen if EQT try to bid them down due to destocking which could well prove to be but a temporary interruption to growth.Thereagain,Co |
Posted at 22/5/2023 07:13 by steeplejack So will EQT adjust its offer to reflect the tough trading conditions currently being encountered.The current price sits near halfway between the price before the bid emerged ie around £26 and the value of the cash bid of a tad over £40.I presume we'll know whether a bid will emerge by June 2,you can't keep kicking the can down the road. |
Posted at 10/5/2023 08:31 by phillis Am not up to date with the rulesDPH could agree to an extension I think |
Posted at 05/9/2022 14:04 by km18 Dechra Pharmaceuticals Plc posted Prelims for the FY ended 30th June 2022. Revenues grew 13.8% to £681.8 million, reported operating profit rose 16.2% to £95.5m, underlying diluted EPS increased 14.0% to 120.84 pence and the FY dividend increased by 10.8% to 44.89 pence, all at constant exchange rate. The business has been growing solidly for many years now, but valuation remains unhelpful with forward PE ratio at 27.9x and PS ratio at 6.21x. Share price has been in a correction for most of 2022 and this correction has extended another 10%+ following today’s release. DPH is a high quality and solid growth business, but it is expensive and a share to monitor for now......from WealthOracle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
